logo-loader
viewReNeuron Group PLC

ReNeuron's lead cell line shows further potential

/**/ sup{font-size:80%}h1{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h2{margin:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h3{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h4{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:16.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h5{margin:0cm;margin-bottom:.0001pt;text-align:justify;text-justify:inter-ideograph;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}h6{margin:0cm;margin-bottom:.0001pt;text-align:right;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .bd{size:595.3pt 841.9pt;margin:72.0pt 106.25pt 49.65pt 90.0pt;}div.bd{}h1.cc{text-indent:117.0pt}span.cd{font-weight:normal}table.cf{margin-left:-5.4pt;border-collapse:collapse}td.ca{width:176.65pt;padding:0cm 5.4pt 0cm 5.4pt}span.cb{font-family:"Calibri","sans-serif"}td.by{width:211.6pt;padding:0cm 5.4pt 0cm 5.4pt}h3.bz{text-align: right}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;} h1.bw{text-align: center}p.cg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: center}p.ch{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: center}p.ci{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-div: italic; text-align: center}span.bt{font-family:"Calibri","sans-serif";color:black}p.cj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-div: italic; text-align: center}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-div: italic; text-align: center}p.cl{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:36.0pt;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-div: italic; text-align: center}p.cm{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align:justify;text-justify:inter-ideograph}span.br{color:black} span.bp{font-family: "Calibri","sans-serif"}p.cn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: justify; text-justify: inter-ideograph}p.co{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";color:black;text-align:justify;text-justify:inter-ideograph}table.cp{width:411.1pt}td.bl{width:67.26%;padding:0cm 0cm 0cm 0cm}p.cq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold}span.bn{font-family:"Calibri","sans-serif"; color:black}td.bj{width:32.74%;padding:0cm 0cm 0cm 0cm}p.cr{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;text-align: right}p.cs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; margin-right: -104.85pt} p.ct{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;font-weight: bold; text-align: right}span.ba{font-family:"Calibri","sans-serif";color:black;}p.cu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:windowtext;margin-bottom:13.5pt}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:15.0pt;margin-left: 0cm;text-align:justify;text-justify:inter-ideograph;background:white} /**/
RNS Number : 7795Q
ReNeuron Group plc
23 October 2019
 

 

 

23 October 2019

AIM: RENE

 

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

ReNeuron's lead cell line shows further potential

 

New data show ReNeuron's lead CTX cell therapy candidate can be

re-programmed into a pluripotent state and differentiated into other cell types

 

These new cell types can be efficiently expanded as potential cell therapy candidates targeting a broad range of diseases

 

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new data relating to its CTX stem cell platform will be presented today at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), a leading scientific conference taking place this week in Barcelona, Spain.

 

Dr Steve Pells, Principal Investigator at ReNeuron, will present new data showing the phenotypic stability and scalability of a mesenchymal stem cell line derived from the Company's proprietary, conditionally immortalised, human neural stem cell line (CTX) following re-programming to a pluripotent state.  

 

The Company has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can be successfully and rapidly re-programmed to an embryonic stem cell-like state enabling differentiation into any cell type. In essence, this means that the Company is able to take its neural stem cells back to being stem cells that can be made to develop into any other type of stem cell including bone, nerve, muscle and skin.

 

The new data being presented today show for the first time that these CTX-iPSCs (induced pluripotent stem cells) can indeed be differentiated along different cell lineages to generate, for example, mesenchymal stem cell lines.  Further, the mesenchymal stem cell lines generated can be grown at scale by virtue of the Company's conditional immortalisation technology, enabling the efficient production of clinical-grade cell therapy candidates.   

 

These results are particularly encouraging as they demonstrate that CTX, a well-characterised, clinical-grade neural stem cell line, could be used to produce new conditionally immortalised allogeneic (i.e. non-donor-specific) cell lines from any of the three primary germ cell layers which form during embryonic development.  ReNeuron is currently exploring the potential to develop further new allogeneic cell lines as potential therapeutic agents in diseases of unmet medical need for subsequent licensing to third parties.

 

Further information about the conference may be found at:

https://www.esgct.eu/congress/barcelona-2019.aspx

 

Commenting on the data, Dr Randolph Corteling, Head of Research at ReNeuron, said:

 

"The data we are presenting at the ESGCT Annual Congress represent a significant advance in the use of cell re-programming to generate new allogeneic cell lines as potential therapeutic candidates.  Importantly, the maintenance of the immortalisation technology within these new cell lines may allow for the scaled production of 'off the shelf' allogeneic stem cells, such as haematopoietic stem cells as a potential alternative approach to those cancer immunotherapies currently in development that rely on the use of the patient's own T-cells."

 

ENDS

 

ENQUIRIES:

 

ReNeuron

 +44 (0)20 3819 8400

Olav Hellebø, Chief Executive Officer


Michael Hunt, Chief Financial Officer


 

Buchanan (UK)

 

+44 (0) 20 7466 5000

Mark Court, Tilly Abraham


 

Argot Partners (US)

Stephanie Marks, Claudia Styslinger

 

Stifel Nicolaus Europe Limited

     

  +1 212 600 1902

        

 

 +44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)


 

N+1 Singer

 

+44 (0) 20 7496 3000

Aubrey Powell, James Moat, Mia Gardner

(Joint Broker)


 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCMMMZGGZRGLZZ

Quick facts: ReNeuron Group PLC

Price: 170.9

Market: LSE
Market Cap: £54.83 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: ReNeuron in active on-going talks for further potential...

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott soon after the release of its interim results to September 2019. The biotech firm says it's in ongoing discussions with “commercial third parties” interested in out-licence deals across all its...

on 9/12/19